Cargando…
Novel prognostic gene signature for pancreatic ductal adenocarcinoma based on hypoxia
BACKGROUND: Currently, there is lack of marker to accurately assess the prognosis of patients diagnosed with pancreatic ductal adenocarcinoma (PDAC). This study aims to establish a hypoxia-related risk scoring model that can effectively predict the prognosis and chemotherapy outcomes of PDAC patient...
Autores principales: | Ren, Min, Feng, Liaoliao, Zong, Rongrong, Sun, Huiru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464224/ https://www.ncbi.nlm.nih.gov/pubmed/37605192 http://dx.doi.org/10.1186/s12957-023-03142-2 |
Ejemplares similares
-
Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma
por: Chen, Dongjie, et al.
Publicado: (2021) -
Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma
por: Chen, Dung-Tsa, et al.
Publicado: (2015) -
Establishing and validating an ADCP-related prognostic signature in pancreatic ductal adenocarcinoma
por: Zhang, Deyu, et al.
Publicado: (2022) -
A Long Non-coding RNA Signature to Improve Prognostic Prediction of Pancreatic Ductal Adenocarcinoma
por: Zhou, Chenhao, et al.
Publicado: (2019) -
Development and Validation of a 7-Gene Prognostic Signature to Improve Survival Prediction in Pancreatic Ductal Adenocarcinoma
por: Feng, Zengyu, et al.
Publicado: (2021)